Abbott, Sanofi to make insulin shots talk to blood sugar tests
Abbott and Sanofi are announcing a partnership today to pair two of their leading product lines.
The non-exclusive collaboration will enable data sharing, at the consent of the user, between the FreeStyle Libre mobile app and connected insulin pens, apps, and cloud software that are currently in development by Sanofi.
Abbott's Freestyle Libre device for continuously measuring blood sugar is a blockbuster product. Sales increased 73% to $433 million in the second quarter, compared to a year ago; investors are awaiting an announcement for approval for a next-generation device. The competition is tough: rival Dexcom has had soaring sales, too.
Sanofi's presence in diabetes, meanwhile, has been diminishing. It's long-acting insulin, Lantus, has been facing new competition. It recently paid Lexicon Pharmaceuticals $260 million to exit a pact to develop a diabetes drug, Zynquista, that had been turned down by the FDA.
The non-exclusive collaboration will enable data sharing, at the consent of the user, between the FreeStyle Libre mobile app and connected insulin pens, apps, and cloud software that are currently in development by Sanofi.
Abbott's Freestyle Libre device for continuously measuring blood sugar is a blockbuster product. Sales increased 73% to $433 million in the second quarter, compared to a year ago; investors are awaiting an announcement for approval for a next-generation device. The competition is tough: rival Dexcom has had soaring sales, too.
Sanofi's presence in diabetes, meanwhile, has been diminishing. It's long-acting insulin, Lantus, has been facing new competition. It recently paid Lexicon Pharmaceuticals $260 million to exit a pact to develop a diabetes drug, Zynquista, that had been turned down by the FDA.
No hay comentarios:
Publicar un comentario